Antigenic composition
View Patent ↗The invention relates to a composition comprising a T cell epitope or a mixture of T cell epitopes a polycationic peptide and a nucleic acid based on inosin and cytosin and its use as a vaccine.
1. A pharmaceutical composition comprising
a) an antigen recognized by T-cells and consisting of 6 to 20 amino acid residues, or a mixture of said antigens;
b) a polycationic peptide; and
c) a nucleic acid based on inosine and cytosine.
2. The composition of claim 1 , wherein the nucleic acid based on inosine and cytosine is poly I: poly C, poly IC, poly dC: poly dI, or poly dIC.
3. The composition of claim 1 , wherein the polycationic peptide is polyarginine, polylysine, or a polypeptide containing at least 50% basic amino acid residues.
4. The composition of claim 3 , wherein the polycationic peptide is a polypeptide containing least 50% arginine residues, lysine residues, or a combination of arginine and lysine residues.
5. The composition of claim 1 , wherein the polycationic peptide contains more than 5 residues.
6. The composition of claim 5 , wherein the polycationic peptide contains between 10 and 1000 residues.
7. The composition of claim 6 , wherein the polycationic peptide contains between 50 and 500 residues.
8. The composition of claim 1 , wherein the antigen is derived from a human, animal or plant pathogen.
9. The composition of claim 1 , wherein the antigen is derived from a viral or bacterial pathogen.
10. The composition of claim 1 , wherein the antigen is derived from a parasite or plant pathogen.
11. The composition of claim 1 , wherein the antigen is further defined as a glycosylated peptide and/or a lipidated peptide.
12. The composition of claim 1 , wherein the antigen is further defined as consisting of 7 to 15 amino acid residues.
13. The composition of claim 12 , wherein the antigen is further defined as consisting of 8 to 11 amino acid residues.
14. The composition of claim 1 , further defined as comprising:
from 1 ng to 1 g of the antigen;
from 1 ng to 1 g of the polycationic peptide; and
from 1 ng to 1 g of the nucleic acid based on inosine and cytosine.
15. The composition of claim 14 , further defined as comprising from 1 to 10000 μg of the antigen.
16. The composition of claim 14 , further defined as comprising from 0.1 to 1000 μg polycationic peptide.
17. The composition of claim 14 , further defined as comprising from 10 μg to 300 mg nucleic acid based on inosine and cytosine.
18. The composition of claim 1 , further comprising at least one auxiliary substance or further effective substance.
19. The composition of claim 1 , further defined as a vaccine.
20. A method of inducing a systemic immune response comprising:
a) obtaining a pharmaceutical composition comprising
i) an antigen recognized by T-cells and consisting of 6 to 20 amino acid residues, or a mixture of said antigens;
ii) a polycationic peptide; and
iii) a nucleic acid based on inosine and cytosine;
b) administering the pharmaceutical composition to a patient.
21. A kit for vaccination comprising:
a) a component containing an antigen recognized by T-cells and consisting of 6 to 20 amino acid residues, or a mixture of said antigens;
b) a polycationic peptide; and
c) a nucleic acid based on inosine and cytosine.
22. A method of eliciting an antigen specific T cell response comprising:
a) obtaining a pharmaceutical composition comprising
i) a component containing an antigen recognized by T-cells and consisting of 6 to 20 amino acid residues, or a mixture of said antigens;
ii) a polycationic peptide; and
iii) a nucleic acid based on inosine and cytosine; and
b) administering the pharmaceutical composition to a patient.